Novartis AG - ADR

5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals

Pharmaceutical acquisitions highlight the promise, risk of new drug development

Obesity, oncology and old age: How 2023 pharmaceutical M&A is reshaping the health-care industry

The Long List of Pharmaceuticals in Short Supply

Big Pharma and The Need for Speed

Could Investors Overdose on Pharmaceuticals?

Voyager Therapeutics Names Alfred Sandrock as CEO, Former Biogen R&D Head

Novartis To Launch New Phase 3 Study To Expand Use of Spinal Muscular Atrophy Drug